Epigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma

OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a poor prognosis. PDAC has poor response to immunotherapy because of its unique tumour microenvironment (TME). In an attempt to stimulate immunologically silent pancreatic cancer, we investigated the role of epigenetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Hong, Young K, Wang, Xingtong, Pandit, Harshul, Zheng, Qianqian, Yu, Youxi, Shi, Xiaoju, Chen, Yujia, Tan, Min, Pulliam, Zachary, Bhutiani, Neal, Lin, Andrew, Badach, Jeremy, Zhang, Ping, Martin, Robert CG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705274/
https://www.ncbi.nlm.nih.gov/pubmed/36452477
http://dx.doi.org/10.1002/cti2.1430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705274/
https://www.ncbi.nlm.nih.gov/pubmed/36452477
http://dx.doi.org/10.1002/cti2.1430

Ejemplares similares